maintenance therapy

Type: Keyphrase
Name: maintenance therapy
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

ODAC Votes No on Accelerated Approval of Olaparib for Ovarian Cancer Maintenance Therapy

Image ToolsSILVER SPRING, MD—The Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration voted 11 to 2 in a meeting here against recommending accelerated approval of olaparib as oral maintenance monotherapy for women with relapsed ... [Published Oncology Times - Jul 23 2014]
First reported Jul 22 2014 - Updated Jul 23 2014 - 1 reports

Sage takes to the FDA fast track with its lead rare disease drug

Sage CEO Jeff JonasFresh off grossing $103.5 million in an over-stuffed IPO, Cambridge, MA's Sage Therapeutics ($SAGE) has secured the promise of a speedy FDA review for its top prospect, a treatment for a rare seizure disorder.The agency has granted ... [Published FierceBiotech - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 2 reports

Opioid Maintenance Therapy: Questions and Controversies | Tessie Castillo

Opioid maintenance therapy, or using a legal opiate to reduce a person's urge to take illicit drugs, has long generated controversy. Scientific evidence supports it as a practical, cost-effective strategy that prevents death and illness generated by street ... [Published DailyMe.Com - Jul 21 2014]
First reported Jul 19 2014 - Updated Jul 19 2014 - 1 reports

Forum Post: My BCG Maintenance Treatment has had to be stopped.

For people affected by bladder cancer to get together, ask questions, share experiences and support each otherMy BCG Maintenance Treatment has had to be stopped.Posted by penroan on19 Jul 2014 11:56 AMHi All,I was diagnosed in Aug 2011 with T1 G3 BC. ... [Published Macmillan Cancer Support - Jul 19 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Sage soars after banking $90M in an up-sized IPO

Sage Therapeutics ($SAGE) rocketed up more than 60% in its first day on Wall Street, bringing in $90 million to bankroll the company's CNS treatments and stirring hopes for a return to bullishness in biotech IPOs.The Cambridge, MA, biotech priced at the ... [Published FierceBiotech - Jul 18 2014]
Entities: IPOs, Biotechnology, Banking
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

Sage up-sizes its ambition on the eve of a much-watched IPO

Biotech luminary Sage Therapeutics is boosting the size of its planned IPO, upping its share offering and expected price range as investors look to its Wall Street debut as a bellwether for the industry.In an amended SEC filing, Sage disclosed that it ... [Published FierceBiotech - Jul 17 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

BiologicTx® Selected As The Specialty Pharmacy For Prospective, Global, Multi-Center, Observational Treatment Registry Study Of Intravenous Immunoglobulin Maintenance Therapy In Alloantibody Positive Renal Allograft Recipients

TOTOWA, N.J., July 17, 2014 /PRNewswire/ -- BiologicTx® was selected as the specialty pharmacy for the observational treatment registry study to evaluate the long-term treatment effects of immune globulin intravenous (IGIV) maintenance therapy on ... [Published PR Newswire: Health - Jul 17 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

Therapy of IBD: What to Expect in the Next Decade

D'Haens G, Deventer SV, Hogenzand RV, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116:1029–1034.Hanauer SB, Feagan BG, Lichtenstein ... [Published General Medicine eJournal - Jul 17 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

Can CAM Therapies Relieve GERD Symptoms?

Désirée A. Lie, MD, MSEdDisclosures July 03, 2014 Case PresentationChristine, a healthy, 65-year-old retired teacher with a body mass index of 29 kg/m 2 , has been treated for gastroesophageal reflux disease (GERD) for the past 4 years. Initially, she ... [Published General Medicine eJournal - Jul 03 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 1 reports

Recurrent Candidiasis

Section Sponsored by:An episode of vulvovaginal candidiasis(VVC) can be inconvenient, but recurrent vulvovaginal candidiasis (RVVC) can be life altering. RVVC is defined as four or more episodes of VVC in a year. An estimated 75% of women experience one ... [Published Advance for NPs and PAs - Jul 02 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Cancer battler, eight, is guest of honour at charity party

Alexander Vaughan, from Chadderton, travelled to London for the special event held by Cancer Research UKA little star has been honoured for shining on despite being faced with cancer.Eight year old Alexander Vaughan, from Chadderton , Oldham , was guest ... [Published Manchester Evening News - Jul 01 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

Olaparib Review Renews Debate On Maintenance Therapy Endpoints

Oncologic Drugs Advisory Committee members divided on whether progression-free survival endpoint in AstaZeneca’s Phase III SOLO-2 trial could be used to support approval for maintenance therapy in relapsed ovarian cancer. ... [Published Health News Daily - Jun 30 2014]

Quotes

...care organizations, brings valuable insight to the company at this pivotal time in the industry," said David Van Sickle, CEO of Propeller Health. "We are excited to have a senior healthcare executive and knowledgeable sales leader like Brad overseeing our customer-focused sales operations."
...of Medicine at Mount Sinai, President-elect of the American Academy of Dermatology and an investigator in the secukinumab clinical trial program. "New and effective treatment options for moderate-to-severe plaque psoriasis are necessary as not every patient responds to existing therapies."
...community regarding the rolapitant pivotal data set presented at the recent ASCO and MASCC conferences," said Lonnie Moulder, CEO of TESARO. "The rolapitant NDA remains on track for submission to the U S FDA in approximately six weeks, and pre-launch commercial activities are well underway. We are also pleased with the pace of enrollment in our Phase 3 niraparib NOVA trial for patients with ovarian cancer, and we expect the non-germline BRCA cohort to be fully enrolled at the end of this year."
...efficacy profile in asthma indication, Relvar's pricing will be key for its favorable placement in the treatment guideline and for driving uptake. "Even though payers across the EU5 have only a modest cost-saving expectation for generic LABA/ICS FDCs and for biosimilar omalizumab, they indicate a strong interest in promoting the usage of these agents, particularly for treatment-naive patients. However, they are less enthusiastic for biosimilar omalizumab, likely due to the lack of experience with biosimilars to date which contributes to payer and physician uncertainty regarding biosimilar omalizumab's safety and bioequivalency to Xolair. This could be mitigated by biosimilar omalizumab demonstrating a robust safety and bioequivalency profile compared to Xolair."

More Content

All (127) | News (113) | Reports (0) | Blogs (13) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Are you Medicare compliant? [Published Chiropractic Economics - 13 hours ago]
Propeller Health Hires Brad Towle as Senior Vic... [Published Scottrade - 21 hours ago]
Novartis announces NEJM publication of two pivo... [Published Drugs.com - Jul 28 2014]
TESARO Announces Second-Quarter 2014 Operating ... [Published Myrtle Beach Sun News - Jul 24 2014]
Celgene's (CELG) CEO, Robert Hugin on Q2 2014 R... [Published Seeking Alpha - Jul 24 2014]
Surveyed EU5 Pulmonologists Expect that Relvar,... [Published Freshnews.com - Jul 24 2014]
Monitoring Disease Activity and Progression in ... [Published Sexual Development - Jul 24 2014]
Surveyed EU5 Pulmonologists Expect that Relvar,... [Published RCL Advisors - Jul 24 2014]
ODAC Votes No on Accelerated Approval of Olapar... [Published Oncology Times - Jul 23 2014]
Break The Silos: Drug Use, HIV, HCV, TB, Laws A... [Published Modern Ghana - Jul 23 2014]
Weekend Wellness: New treatments for dry eyes m... [Published Mayo Clinic College of Medicine - Jul 23 2014]
Breaking the ‘Silos’ of Drug Use [Published Asia Sentinel - Jul 23 2014]
Sage takes to the FDA fast track with its lead ... [Published FierceBiotech - Jul 22 2014]
Revlimid, Velcade, and Dexamethasone Followed b... [Published CancerConnect.com - Jul 22 2014]
Opioid Maintenance Therapy: Questions and Contr... [Published DailyMe.Com - Jul 21 2014]
Opioid Maintenance Therapy: Questions and Contr... [Published Huffington Post - Jul 21 2014]
Weekend Wellness: New treatments for dry eyes m... [Published Noodls - Jul 19 2014]
Forum Post: My BCG Maintenance Treatment has ha... [Published Macmillan Cancer Support - Jul 19 2014]
Sage soars after banking $90M in an up-sized IPO [Published FierceBiotech - Jul 18 2014]
Deep Venous Thrombosis: The “Economy Class Synd... [Published U.S.Pharmacist - Jul 17 2014]
Sage up-sizes its ambition on the eve of a much... [Published FierceBiotech - Jul 17 2014]
BiologicTx® Selected As The Specialty Pharmacy ... [Published PR Newswire: Health - Jul 17 2014]
Therapy of IBD: What to Expect in the Next Decade [Published General Medicine eJournal - Jul 17 2014]
Theravance/Glaxo Commence Global Late stage Stu... [Published Yahoo! Finance - Jul 16 2014]
ONLINE FIRST: Metastatic Colorectal Cancer: Upd... [Published Oncology Times - Jul 16 2014]
IgG4 Cholangiopathy: A Diagnostic and Therapeut... [Published General Medicine eJournal - Jul 15 2014]
Pregnant Texas Woman Denied Methadone Treatment... [Published RHRealityCheck - Jul 15 2014]
Arizona Care Network Is First ACO to Launch Pro... [Published Pettinga Financial Advisors - Jul 14 2014]
Arizona Care Network Is First ACO to Launch Pro... [Published TickerTech.com - Jul 14 2014]
Hanmi Pharmaceuticals and Collaborative Partner... [Published Pharmacy Choice - Jul 14 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
BiologicTx® Selected As The Specialty Pharmacy ... [Published PR Newswire: Health - Jul 17 2014]
TOTOWA, N.J., July 17, 2014 /PRNewswire/ -- BiologicTx® was selected as the specialty pharmacy for the observational treatment registry study to evaluate the long-term treatment effects of immune globulin intravenous (IGIV) maintenance therapy on ...
RheumShorts: Vasculitis, MRI, Anakinra for Knee... [Published MedPageToday.com - medical news plus CME for ph ... - Jun 29 2014]
(MedPage Today) -- The rheumatology literature this week explored whether or not patients with vasculitis treated with rituximab also need maintenance therapy, if MRI can predict later arthritis when disease is still subclinical, and how an interleukin ...
Orexo: Positive Top-Line Results from Two Phase... [Published Business Wire Health News - Jun 23 2014]
UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo (STO:ORX) Orexo AB (publ) announces the results of two clinical trials assessing Zubsolv for induction of buprenorphine maintenance therapy in patients with opioid dependence. Combined data from ...
Treg function depleted by Daclizumab but functi... [Published Multiple Sclerosis Research - Jun 19 2014]
Oh U, Blevins G, Griffith C, Richert N, Maric D, Lee CR, McFarland H, Jacobson S. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol. 2009 Apr;66(4):471-9. doi: 10.1001/archneurol.2009.16.OBJECTIVE:Maintenance ...
RheumShorts: New Knees, Lupus Med Switches (CME... [Published MedPageToday.com - medical news plus CME for ph ... - May 15 2014]
(MedPage Today) -- The news in rheumatology this week included reports on knee replacements in the Dominican Republic, outcomes with scleroderma overlap disease, and reasons for switching maintenance therapy in lupus. ...
1 2 3

Press Releases

sort by: Date | Relevance
Positive Top-line Results from Two Phase 3 Clin... [Published GlobeNewswire: Advertising News - Jun 23 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.